Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Dermatology Companies

Teva has brief "at risk" launch of generic Solodyn, then settles

This article was originally published in Scrip

Executive Summary

Teva Pharmaceutical Industries halted its "at risk" launch of a generic version of Medicis Pharmaceutical's acne drug Solodyn (minocycline HCl) extended-release tablets in the US just hours after it announced shipping had begun. The halt in shipping occurred as a result of a settlement with Medicis, which was rebuffed by the FDA, along with several other manufacturers, seeking to have 30-month stays imposed on ANDAs for certain "old" antibiotics.

Table

View full table

Topics

Related Companies

Tags:
Dermatology Companies
Latest Headlines

Avistone Wins China Approval For First C-Met Inhibitor In Glioblastoma

Are Jubilant Pharmova’s US Plant Closure, FDA Observations At Canada Unit A Concern?

X4 Gets First Approval In Ultra-Rare Disorder, Needs Time To Build A Market

Ono Buys Deciphera, Gaining A Commercial Cancer Drug And Infrastructure

See All
UsernamePublicRestriction

Register

SC001025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By